Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy

Experimental Hematology

Volumn 39, Issue 1, 2011, Pages

  Jalkanen, Sari E ^a   Vakkila, Jukka ^a   Kreutzman, Anna ^a   Nieminen, Janne K ^b   Porkka, Kimmo ^a   Mustjoki, Satu ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; DASATINIB; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5A PROTEIN; STAT6 PROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CD4+ CD25+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOID CELL; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 78650223306     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.09.005     Document Type: Article

References (53)

1. Hehlmann R., Hochhaus A., Baccarani M. Chronic myeloid leukaemia. Lancet 2007, 370:342-350.
2. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18:189-218.
3. Carlesso N., Frank D.A., Griffin J.D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996, 183:811-820.
4. Ilaria R.L., Van Etten R.A. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996, 271:31704-31710.
5. Scherr M., Chaturvedi A., Battmer K., et al. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 2006, 107:3279-3287.
6. Van Etten R.A. Aberrant cytokine signaling in leukemia. Oncogene 2007, 26:6738-6749.
7. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
8. Srinivasan M., Frauwirth K.A. Peripheral tolerance in CD8+ T cells. Cytokine 2009, 46:147-159.
9. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000, 6:1018-1023.
10. Rezvani K., Grube M., Brenchley J.M., et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003, 102:2892-2900.
11. Molldrem J.J., Lee P.P., Kant S., et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003, 111:639-647.
12. Mumprecht S., Schurch C., Schwaller J., Solenthaler M., Ochsenbein A.F. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009, 114:1528-1536.
13. Eisendle K., Lang A., Eibl B., et al. Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. Br J Haematol 2003, 120:63-73.
14. Mohty M., Jourdan E., Mami N.B., et al. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood 2004, 103:4666-4668.
15. Shah N.P., Nicoll J.M., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
16. Hantschel O., Rix U., Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008, 49:615-619.
17. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
18. Hochhaus A., O'Brien S.G., Guilhot F., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
19. Al-Ameri A., Kantarjian H., Borthakur G., et al. Opportunistic infections are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP). Blood 2009, 114. Abstract 1120.
20. Sillaber C., Herrmann H., Bennett K., et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 2009, 39:1098-1109.
21. Kim D.H., Kamel-Reid S., Chang H., et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009, 94:135-139.
22. Mustjoki S., Ekblom M., Arstila T.P., et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009, 23:1398-1405.
23. Marodi L., Goda K., Palicz A., Szabo G. Cytokine receptor signalling in neonatal macrophages: defective STAT-1 phosphorylation in response to stimulation with IFN-gamma. Clin Exp Immunol 2001, 126:456-460.
24. Irish J.M., Hovland R., Krutzik P.O., et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004, 118:217-228.
25. Lesinski G.B., Kondadasula S.V., Crespin T., et al. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst 2004, 96:1331-1342.
26. Montag D.T., Lotze M.T. Successful simultaneous measurement of cell membrane and cytokine induced phosphorylation pathways CIPP] in human peripheral blood mononuclear cells. J Immunol Methods 2006, 313:48-60.
27. Tochizawa S., Masumori N., Yanai Y., Ohmoto Y., Yabuuchi Y., Tsukamoto T. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines. Biomed Res 2008, 29:271-278.
28. Vakkila J., Nieminen U., Siitonen S., et al. A novel modification of a flow cytometric assay of phosphorylated STAT1 in whole blood monocytes for immunomonitoring of patients on IFN alpha regimen. Scand J Immunol 2008, 67:95-102.
29. Kim K.I., Park J., Ahn K.S., et al. Molecular characterization and prognostic significance of FLT3 in CML progression. Leuk Res 2010, 34:995-1001.
30. Irish J.M., Kotecha N., Nolan G.P. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 2006, 6:146-155.
31. Krutzik P.O., Irish J.M., Nolan G.P., Perez O.D. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 2004, 110:206-221.
32. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004, 4:469-478.
33. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342.
34. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975, 45:321-334.
35. Gutierrez-Castellanos S., Cruz M., Rabelo L., Godinez R., Reyes-Maldonado E., Riebeling-Navarro C. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients. Eur J Haematol 2004, 72:231-238.
36. Gasson J.C. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991, 77:1131-1145.
37. Tao M., Li B., Nayini J., et al. SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine 2000, 12:699-707.
38. Sergeeva A., Ono Y., Rios R., Molldrem J.J. High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease. Leukemia 2008, 22:783-790.
39. Lee J., Kim Y., Lim J., Kim M., Han K. G-CSF and GM-CSF concentrations and receptor expression in peripheral blood leukemic cells from patients with chronic myelogenous leukemia. Ann Clin Lab Sci 2008, 38:331-337.
40. Balleari E., Bason C., Visani G., Gobbi M., Ottaviani E., Ghio R. Serum levels of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in treated patients with chronic myelogenous leukemia in chronic phase. Haematologica 1994, 79:7-12.
41. Niu G., Bowman T., Huang M., et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002, 21:7001-7010.
42. Steinbrink K., Wolfl M., Jonuleit H., Knop J., Enk A.H. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997, 159:4772-4780.
43. Williams L., Bradley L., Smith A., Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 2004, 172:567-576.
44. Asseman C., Mauze S., Leach M.W., Coffman R.L., Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999, 190:995-1004.
45. Gabrilovich D.I., Chen H.L., Girgis K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2:1096-1103.
46. Kinjyo I., Inoue H., Hamano S., et al. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med 2006, 203:1021-1031.
47. Kortylewski M., Kujawski M., Wang T., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005, 11:1314-1321.
48. Silva C.M. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004, 23:8017-8023.
49. Pallandre J.R., Brillard E., Crehange G., et al. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J Immunol 2007, 179:7593-7604.
50. Kreutzman A., Juvonen V., Kairisto V., et al. Mono/oligoclonal T- and NK-cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010, 116:772-782.
51. Cwynarski K., Laylor R., Macchiarulo E., et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004, 18:1332-1339.
52. Fei F., Yu Y., Schmitt A., et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 2008, 36:1297-1308.
53. Blake S., Hughes T.P., Mayrhofer G., Lyons A.B. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008, 127:330-339.